SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| MICHAS ALEXIS P | Director | 2026-08-25 | Gift | 285 | $0 |
| Goldberg Joel S | Please See Remarks | 2026-08-14 | Gift | 27785 | $0 |
| Goldberg Joel S | Please See Remarks | 2026-08-14 | Gift | 27785 | $0 |
| Singh Prahlad R. | Please See Remarks, Director | 2026-08-13 | Gift | 7636 | $0 |
| Singh Prahlad R. | Please See Remarks, Director | 2026-08-13 | Gift | 7636 | $0 |
| Singh Prahlad R. | Please See Remarks, Director | 2026-08-13 | Gift | 59650 | $0 |
| Singh Prahlad R. | Please See Remarks, Director | 2026-08-13 | Gift | 59650 | $0 |
| Gonzales Anita | Vice President and CAO | 2026-07-20 | Open-market sell 10b5-1 | 85 | $9K |
| Gonzales Anita | Vice President and CAO | 2026-06-15 | Tax withholding | 33 | $3K |
| Barrett Peter | Director | 2026-05-07 | Grant/award | 1015 | $0 |
| Barrett Peter | Director | 2026-05-07 | Grant/award | 1265 | $0 |
| Chapin Samuel R. | Director | 2026-05-07 | Grant/award | 1015 | $0 |
| Chapin Samuel R. | Director | 2026-05-07 | Grant/award | 1265 | $0 |
| Klobuchar Michael A | Director | 2026-05-07 | Grant/award | 1015 | $0 |
| Klobuchar Michael A | Director | 2026-05-07 | Grant/award | 1265 | $0 |
| MICHAS ALEXIS P | Director | 2026-05-07 | Grant/award | 1217 | $0 |
| MICHAS ALEXIS P | Director | 2026-05-07 | Grant/award | 1467 | $0 |
| McMurry-Heath Michelle | Director | 2026-05-07 | Grant/award | 1015 | $0 |
| McMurry-Heath Michelle | Director | 2026-05-07 | Grant/award | 1265 | $0 |
| Vandebroek Sophie V. | Director | 2026-05-07 | Grant/award | 1015 | $0 |
Fiscal period ending 2025-12-28 versus 2024-12-29 — view filing on EDGAR →
Tariff exposure is now quantified at $25M in costs and $20M in margin reduction, with forward-looking warnings of further material adverse effects — a concrete escalation of trade risk. Simultaneously, new disclosures on U.S. funding/regulatory shifts and AI deployment risks broaden the risk profile across macro and technology dimensions. The combined effect is a meaningfully wider risk picture, though no solvency or existential threat is indicated.
1 company-specific · 2 common-mode
New quantified tariff impact ($25M cost, $20M margin reduction) and forward-looking warning of material adverse effects from future tariffs materially escalates trade risk disclosure.
Risks Related to our Foreign Operations Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability. Because we sell our…
New disclosure of "recently announced and proposed changes in U.S. funding and regulations" creating "more cautious spending environment" escalates regulatory/funding risk beyond generic boilerplate.
Risks Related to our Business Operations and Industry If the markets into which we sell our products decline or do not grow as anticipated due to a decline in general economic conditions, or there…
New disclosure of material AI deployment risks: operational disruption, competitive disadvantage, significant capex/labor costs, and regulatory/legal exposure in evolving landscape.
Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation. We are advancing…
Revvity announced Q2 2026 financial results on August 4, 2026, disclosing revenue of $730 million, GAAP EPS of $0.48, and adjusted EPS of $1.41, along with raising full-year pro forma revenue guidance to $2.83–$2.86 billion.
View raw filing on EDGAR →Revvity entered into a definitive agreement on July 31, 2026 to divest its Immunodiagnostics business in China for up to $200 million, subject to adjustments and closing conditions, with expected close by end of 2027. The divestiture represents approximately 6% of 2025 revenue.
View raw filing on EDGAR →